Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 24, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 23, 2026
CEOIndirect holdingOther
Context
Classification
other
Code P in the derivative table; not an open-market share purchase
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-279703
Filed / recorded
Jun 23, 2026, 8:56 PM UTC
Added to OQRO
Oct 8, 2026, 2:17 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Tempest Therapeutics, Inc.
Issuer CIK
1544227
Ticker
TPST
Reporting person
Matthew Angel
Relationship
Director, Officer, 10% owner
Officer title
CEO and President
Security
Series A Warrant (right to buy)
Table
Derivative (Table II)
Transaction date
Mar 24, 2026
Transaction code
P
Shares / units
231,482
Acquired / disposed
Acquired (A)
Shares owned after
231,482
Ownership form
Indirect — By Factor Bioscience Inc.
Amendment
No
Footnotes from the filing
On March 24, 2026, Factor Biosciences Inc. ("Factor") acquired 231,482 shares of common stock, par value $0.001 per share, of Tempest Therapeutics, Inc. ("Common Stock") and warrants to purchase 462,964 shares of Common Stock (the "Warrants"), pursuant to a Securities Purchase Agreement by and between the Issuer, Factor and two institutional investors, dated as of March 20, 2026.
The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
The Series A Warrants are subject to the approval of the Company's stockholders. The Series A Warrants will become exercisable on the effective date of the stockholder approval and have a term of five years from the effective date of the stockholder approval.
The Reporting Person is the majority stockholder and Chairman of the Board of Directors of Factor and exercises voting and investment power over the shares held by Factor.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.